Last week on-demand healthcare concierge for provider employers Accolade received $50 million in funding led by Andreessen Horowitz, Carrick Capital Partners, Madrona Venture Group, and McKesson Ventures, with participation from Cross Creek Advisors and Madera Technologies. The company plans to use the money to grow its workforce, look at new market opportunities, and expand its Personalized Advocacy platform.
from MobiHealthNews https://ift.tt/2GujvPm
April 03, 2018
Rose
MobiHealthNews
No comments
Related Posts:
NYT, Bloomberg say Apple is working on Watch EKG, noninvasive glucoseCiting anonymous sources within Apple, reports in Bloomberg and the New York Times over the past weeks continue to add to the pile of leaks and rumors about two of Apple's currently under-developme from MobiHealthNews http:/… Read More
Study: "Artificial pancreas" could help youth with diabetes participate in intense activitiesUsing an artificial pancreas (closed-loop control system) could make it easier for adolescents with Type 1 diabetes to participate in intensive outdoor physical activities, according to a study published in Diabetes Care.&nbs… Read More
Pear Therapeutics rakes in $50M to develop additional digital therapeuticsBoston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company … Read More
MedStar Health partners with startup to pilot prenatal appMedStar Health announced that it will begin offering expectant mothers a “Mommy Kit” containing an iPhone app, wireless weight scale, and wireless blood pressure cuff. The not-for-profit health system in Maryland and th… Read More
CMS clarifies policy on texting patient info within healthcare teamsFollowing some confusion, a Survey & Certification Letter sent last week has reaffirmed CMS’s stance on texting patient information, specifying that messages sent among clinicians are permissible so long as healthcare tea… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment